Papyrus Australia has commissioned its Adelaide Rapid Prototyping & R&D Facility, marking a key step in validating its pulp technology and progressing towards commercial production. The company also released its interim financials and reported stable cash flow supporting ongoing operations.
- Adelaide R&D facility commissioned and operational
- Core research on pulp optimisation and equipment scale-up underway
- Production of moulded product samples and pulp for contract trials
- Interim financial report released for half-year ending December 2025
- Cash reserves and loan facilities support over 11 months of funding
Operational Milestone Achieved
In February 2026, Papyrus Australia Ltd reached a significant milestone with the commissioning and early operation of its Adelaide Rapid Prototyping & R&D Facility. This development transitions the company from installation to active production, enabling accelerated validation of its innovative pulp technology. The facility is now central to Papyrus’ commercialisation strategy, supporting product development and scale-up planning.
The R&D facility is currently engaged in refining pulp furnish blends tailored for various moulded and board products, a critical step in ensuring product performance meets market requirements. Concurrently, equipment design optimisation trials are underway to improve material flow and prepare for future commercial-scale manufacturing.
Product Development and Contract Support
Initial moulding runs have produced prototype trays and other sample products that meet quality benchmarks, reinforcing confidence in the scalability of Papyrus’ technology. Additionally, the facility is producing pulp specifically for the TBS contract board trials, a vital component in validating the fibre technology for commercial board production and fulfilling contractual commitments.
Financial Position and Cash Flow
Alongside operational progress, Papyrus released its Interim Financial Report for the half-year ending 31 December 2025, providing shareholders with transparency on the company’s financial health. The February 2026 Appendix 4C cash flow report highlights ongoing expenditures primarily related to prototyping equipment procurement and overhead costs such as staff and legal fees.
Importantly, Papyrus maintains a solid cash position with $344,000 in cash and $250,000 in unused loan facilities, collectively supporting an estimated 11.4 months of operations at current cash burn rates. The company’s loan facilities include a $500,000 unsecured loan due in April 2026 and a $250,000 facility with drawdowns at the board’s discretion.
Looking Ahead
With the R&D facility now operational and delivering meaningful outputs, Papyrus is well positioned to advance its commercial strategy. The company’s focus remains on strengthening its technology platform, validating products with customers, and preparing for scale-up and revenue generation. However, the approaching maturity of the $500,000 loan facility in April 2026 will require careful financial management or refinancing to maintain momentum.
Bottom Line?
Papyrus’ operational and financial progress sets a promising stage, but upcoming financing decisions will be pivotal for sustaining its commercialisation trajectory.
Questions in the middle?
- How will Papyrus manage the $500,000 loan facility maturing in April 2026?
- What timelines can investors expect for transitioning from R&D to commercial production?
- How will customer and partner engagements evolve following the production of prototype samples?